No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Dermata Therapeutics, Inc. (DRMA) stock was $1.11 as of Oct 5, 2026, 4:00 PM EDT, up 0.45% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -77.0% · 3-year avg -80.2%/yr · 5-year avg -83.9%/yr
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States.
Biotechnology · San Diego, CA
LATEST PRICE
$1.11
52-WEEK RANGE
$0.95 - $5.18
BETA
0.69
% FROM 52W HIGH
-78.57%
MARKET CAP
$4.46M
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
1.28
P/S RATIO
TTM
N/A
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
0.00
REVENUE TTM
$0
GROSS MARGIN TTM
0.00%
NET PROFIT MARGIN TTM
0.00%
REVENUE GROWTH TTM
TTM vs prior TTM
N/A
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
-77.00%
3Y TOTAL RETURN
annualized (CAGR)
-80.18%
5Y TOTAL RETURN
annualized (CAGR)
-83.90%
Next Earnings Date
Nov 18, 2026
43 days away
EPS Estimate
-0.55
Revenue Est.
$25000.00
Last Quarter Results
EPS
$-0.74
vs Estimate
$-0.55
Revenue
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 1 analyst
Average Price Target
$4.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Quarter ending Dec 2026 | $-0.46 | $-0.46 | $-0.46 | 1 |
| Quarter ending Mar 2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
| Quarter ending Jun 2027 |
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1DRMA | $4.46M | $1.11 | +0.45% | -77.00% | -83.90% | N/A | N/A |
| 2CLGN | $4.42M | $3.41 | -1.45% | -85.66% | -53.69% | N/A | vs DRMA |
| 3ERNA | $4.41M | $2.70 | -8.78% | -90.95% | -86.83% | -65.14% | vs DRMA |
| 4AIDX | $4.32M | $0.35 | -7.26% | N/A | N/A | N/A | vs DRMA |
| 5GRI | $4.18M | $1.91 | -2.55% | -96.44% | -95.39% | N/A | vs DRMA |
| 6BGMS | $4.79M | $0.87 | -1.32% | -81.68% | N/A | N/A | vs DRMA |
+260.4% upside
Low
$4.00
Current
$1.11
High
$4.00
| $-0.36 |
| $-0.36 |
| $-0.36 |
| 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.17 | $-2.17 | $-2.17 | 1 |
| FY 2027 | $-1.43 | $-1.43 | $-1.43 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $25000.00 | $25000.00 | $25000.00 | 1 |
| Quarter ending Dec 2026 | $75000.00 | $75000.00 | $75000.00 | 1 |
| Quarter ending Mar 2027 | $100000.00 | $100000.00 | $100000.00 | 1 |
| Quarter ending Jun 2027 | $150000.00 | $150000.00 | $150000.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $100000.00 | $100000.00 | $100000.00 | 1 |
| FY 2027 | $750000.00 | $750000.00 | $750000.00 | 1 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
